Reduced Gray Matter Volume in Normal Adults with a Maternal Family History of Alzheimer Disease

Overview

Journal Neurology

Specialty Neurology

Date 2010 Jan 13

PMID 20065246

Citations 72

Authors

R A Honea

R H Swerdlow

E D Vidoni

J Goodwin

J M Burns

Affiliations

Soon will be listed here.

Abstract

Objective: A consistently identified risk factor for Alzheimer disease (AD) is family history of dementia, with maternal transmission significantly more frequent than paternal transmission. A history of maternal AD may be related to AD-like glucose consumption in cognitively healthy subjects. In this cross-sectional study, we tested whether cognitively healthy people with a family history of AD have less gray matter volume (GMV), an endophenotype for late-onset AD, than individuals with no family history, and whether decreases in GMV are different in subjects with a maternal family history.

Methods: As part of the Kansas University Brain Aging Project, 67 cognitively intact individuals with a maternal history of late-onset AD (FHm, n = 16), a paternal history of AD (FHp, n = 8), or no parental history of AD (FH-, n = 43), similar in age, gender, education, and Mini-Mental State Examination score, were scanned at 3 T. We used voxel-based morphometry to examine GMV differences between groups, controlling for age, gender, and apoE4.

Results: Cognitively healthy individuals with a family history of late-onset AD had significantly decreased GMV in the precuneus, middle frontal, inferior frontal, and superior frontal gyri compared with FH- individuals. FHm subjects had significantly smaller inferior frontal, middle frontal, precuneus, and lingual gyri compared with FH- and FHp subjects.

Conclusions: Overall, maternal family history of Alzheimer disease (AD) in cognitively normal individuals is associated with lower gray matter volume in AD-vulnerable brain regions. These data complement and extend reports of cerebral metabolic differences in subjects with a maternal family history.

Citing Articles

TOMM40 may mediate GFAP, neurofilament light Protein, pTau181, and brain morphometry in aging.

Honea R, Wilkins H, Hunt S, Kueck P, Burns J, Swerdlow R Aging Brain. 2025; 7:100134.

PMID: 39760103 PMC: 11699468. DOI: 10.1016/j.nbas.2024.100134.

Impact of Apolipoprotein E ε4 in Alzheimer's Disease: A Meta-Analysis of Voxel-Based Morphometry Studies.

Bailey M, Ilchovska Z, Hosseini A, Jung J J Clin Neurol. 2024; 20(5):469-477.

PMID: 39227329 PMC: 11372214. DOI: 10.3988/jcn.2024.0176.

Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia.

Ferguson E, Thoma M, Buto P, Wang J, Glymour M, Hoffmann T JAMA Netw Open. 2024; 7(7):e2424539.

PMID: 39078629 PMC: 11289698. DOI: 10.1001/jamanetworkopen.2024.24539.

Automated detection of Alzheimer's disease: a multi-modal approach with 3D MRI and amyloid PET.

Castellano G, Esposito A, Lella E, Montanaro G, Vessio G Sci Rep. 2024; 14(1):5210.

PMID: 38433282 PMC: 10909869. DOI: 10.1038/s41598-024-56001-9.

Alzheimer's disease cortical morphological phenotypes are associated with TOMM40'523-APOE haplotypes.

Honea R, Hunt S, Lepping R, Vidoni E, Morris J, Watts A Neurobiol Aging. 2023; 132:131-144.

PMID: 37804609 PMC: 10763175. DOI: 10.1016/j.neurobiolaging.2023.09.001.

References

Gomez-Tortosa E, Barquero M, Baron M, Sainz M, Manzano S, Payno M . Variability of age at onset in siblings with familial Alzheimer disease. Arch Neurol. 2007; 64(12):1743-8. DOI: 10.1001/archneur.64.12.1743. View

Cupples L, Farrer L, Sadovnick A, Relkin N, Whitehouse P, Green R . Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med. 2004; 6(4):192-6. DOI: 10.1097/01.gim.0000132679.92238.58. View

Mosconi L, Sorbi S, de Leon M, Li Y, Nacmias B, Myoung P . Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med. 2006; 47(11):1778-86. View

Coskun P, Beal M, Wallace D . Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A. 2004; 101(29):10726-31. PMC: 490002. DOI: 10.1073/pnas.0403649101. View

Misra C, Fan Y, Davatzikos C . Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage. 2008; 44(4):1415-22. PMC: 2648825. DOI: 10.1016/j.neuroimage.2008.10.031. View

Reiman E . Linking brain imaging and genomics in the study of Alzheimer's disease and aging. Ann N Y Acad Sci. 2007; 1097:94-113. DOI: 10.1196/annals.1379.011. View

Edland S, Silverman J, Peskind E, Tsuang D, Wijsman E, Morris J . Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology. 1996; 47(1):254-6. DOI: 10.1212/wnl.47.1.254. View

Morris J . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-4. DOI: 10.1212/wnl.43.11.2412-a. View

Johnson S, Schmitz T, Trivedi M, Ries M, Torgerson B, Carlsson C . The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci. 2006; 26(22):6069-76. PMC: 2684824. DOI: 10.1523/JNEUROSCI.0959-06.2006. View

10.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

11.

Mosconi L, Brys M, Switalski R, Mistur R, Glodzik L, Pirraglia E . Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci U S A. 2007; 104(48):19067-72. PMC: 2141909. DOI: 10.1073/pnas.0705036104. View

12.

Duara R, Barker W, Loewenstein D, Grau L, Gilchrist D, Sevush S . Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. Neurology. 1996; 46(6):1575-9. DOI: 10.1212/wnl.46.6.1575. View

13.

Kinkingnehun S, Sarazin M, Lehericy S, Guichart-Gomez E, Hergueta T, Dubois B . VBM anticipates the rate of progression of Alzheimer disease: a 3-year longitudinal study. Neurology. 2008; 70(23):2201-11. DOI: 10.1212/01.wnl.0000303960.01039.43. View

14.

Hirai K, Aliev G, Nunomura A, Fujioka H, Russell R, Atwood C . Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 2001; 21(9):3017-23. PMC: 6762571. View

15.

Parker Jr W, Filley C, Parks J . Cytochrome oxidase deficiency in Alzheimer's disease. Neurology. 1990; 40(8):1302-3. DOI: 10.1212/wnl.40.8.1302. View

16.

Reiman E, Caselli R, Yun L, Chen K, Bandy D, Minoshima S . Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996; 334(12):752-8. DOI: 10.1056/NEJM199603213341202. View

17.

Honea R, Vidoni E, Harsha A, Burns J . Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J Alzheimers Dis. 2009; 18(3):553-64. PMC: 2892293. DOI: 10.3233/JAD-2009-1163. View

18.

Iacono D, Markesbery W, Gross M, Pletnikova O, Rudow G, Zandi P . The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology. 2009; 73(9):665-73. PMC: 2734290. DOI: 10.1212/WNL.0b013e3181b01077. View

19.

Burns J, Cronk B, Anderson H, Donnelly J, Thomas G, Harsha A . Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. Neurology. 2008; 71(3):210-6. PMC: 2657657. DOI: 10.1212/01.wnl.0000317094.86209.cb. View

20.

Mosconi L, Mistur R, Switalski R, Brys M, Glodzik L, Rich K . Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology. 2008; 72(6):513-20. PMC: 2677512. DOI: 10.1212/01.wnl.0000333247.51383.43. View